(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.08%) $0.927
(0.29%) $10.87
(0.03%) $0.792
(-0.15%) $92.44
@ $11.29
Issued: 13 Feb 2024 @ 15:33
Return: -6.91%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 2.98 %
Live Chart Being Loaded With Signals
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States...
Stats | |
---|---|
Today's Volume | 1.03M |
Average Volume | 522 655 |
Market Cap | 1.08B |
EPS | $0 ( 2024-03-19 ) |
Next earnings date | ( $-0.740 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.08 |
ATR14 | $0.0170 (0.16%) |
Volume Correlation
Immatics N.V. Correlation
10 Most Positive Correlations | |
---|---|
RMRM | 0.966 |
RXT | 0.929 |
SWAV | 0.925 |
UCBI | 0.922 |
NFE | 0.918 |
CCRN | 0.917 |
NVTSW | 0.916 |
GBCI | 0.915 |
FIBK | 0.914 |
THTX | 0.914 |
10 Most Negative Correlations | |
---|---|
MLCO | -0.927 |
EZGO | -0.926 |
RXDX | -0.925 |
FWONK | -0.922 |
BRAC | -0.92 |
LUNA | -0.918 |
HWCC | -0.917 |
BKNG | -0.917 |
MLVF | -0.916 |
MOMO | -0.915 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Immatics N.V. Correlation - Currency/Commodity
Immatics N.V. Financials
Annual | 2023 |
Revenue: | $54.00M |
Gross Profit: | $54.00M (100.00 %) |
EPS: | $-1.200 |
Q4 | 2023 |
Revenue: | $15.92M |
Gross Profit: | $15.92M (100.00 %) |
EPS: | $-0.310 |
Q3 | 2023 |
Revenue: | $5.93M |
Gross Profit: | $5.93M (100.00 %) |
EPS: | $-0.320 |
Q2 | 2023 |
Revenue: | $22.35M |
Gross Profit: | $-4.96M (-22.20 %) |
EPS: | $-0.320 |
Financial Reports:
No articles found.
Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators